| Literature DB >> 28387832 |
Amy L Lightner1, William A Faubion2.
Abstract
Perianal Crohn's disease [CD] is found in a quarter of patients with CD and remains notoriously difficult to treat. Several medical and surgical therapies are available. However, none is particularly effective nor reliably provides sustained remission. In addition, surgical intervention is complicated by poor healing and the potential for incontinence. Mesenchymal stem cell-based therapies provide a promising treatment alternative for perianal CD, with demonstrated safety, improved efficacy, and a decreased side effect profile. Several phase I, II, and now III randomised controlled trials have now reported safety and efficacy in treating perianal CD. The aim of this review is to discusses the outcomes of conventional treatment approaches, outcomes of mesenchymal stem cell therapies, considerations specific to stem cell-based therapies, and future directions for research.Entities:
Keywords: Crohn’s disease; Stem cells; perianal fistula
Mesh:
Year: 2017 PMID: 28387832 DOI: 10.1093/ecco-jcc/jjx046
Source DB: PubMed Journal: J Crohns Colitis ISSN: 1873-9946 Impact factor: 9.071